KainosMed Participates in JPMHC... Discusses Joint Business Development for Parkinson's Disease Treatment

Kynosmed will participate in the United States' largest pharmaceutical and biotech investment conference, the '2024 JP Morgan Healthcare Conference (JPMHC)'.

The 42nd JPMHC, held from January 8 to 11 next year in San Francisco, California, is the largest event in the pharmaceutical and biotech investment industry. It is expected to gather 600 pharmaceutical, biotech, and healthcare companies along with over 8,000 corporate representatives and investors in one place. Kynosmed has continuously participated in the conference together with its U.S. subsidiary, Fascinate Therapeutics.

At this conference, Kynosmed will be represented by Vice Chairman Kim In-cheol and President Lee Jae-moon. They plan to hold partnering meetings with global pharmaceutical companies to specifically discuss the technology introduction and joint business development of KM-819, which is being developed as a treatment for Parkinson's disease.

The industry is paying close attention to Kynosmed’s ongoing Phase 2 clinical trial for Parkinson's disease in the U.S. and the Phase 2 clinical trial for multiple system atrophy in Korea, both conducted by its subsidiary Fascinate Therapeutics. Many companies are highly interested in clinical stages for incurable diseases without existing treatments, and it is known that follow-up meetings are being sought at the conference.

A Kynosmed representative stated, "The clinical progress of our main pipeline, the Parkinson's disease treatment, is proceeding smoothly, generating significant interest in global markets including the U.S. Based on our successful technology transfer experience with AIDS treatments, we will devote all efforts to successfully completing clinical trials for Parkinson's disease and multiple system atrophy treatments."